RA is characterised by inflammation of the synovial joints. This can lead to progressive joint destruction and consequently impair the quality of life.
It is generally accepted that early intervention is vital in preventing irreversible joint damage and therefore it is important to diagnose RA as early in the disease course as possible.
New classification criteria for rheumatoid arthritis (RA) were published in 2010. The revised criteria have been approved by the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR). These new RA classification criteria follow recommendations at the 2009 ACR Congress and will allow clinicians to focus on the important need for earlier diagnosis and more effective early therapeutic intervention. The outcome of the new criteria means that ACPA (principally anti-CCP antibodies) testing has been added to the biochemical criteria for disease classification, in addition to the long established sole blood test, the relatively non-specific Rheumatoid Factor assay.
This formally recognised the importance of testing for anti-CCP antibodies in the early detection of rheumatoid arthritis from the major global authorities on this potentially debilitating disease. Anti-CCP is a key marker for Axis-Shield and this inclusion reinforces the importance of protecting our IP on anti-CCP testing.
For more details on our Anti-CCP assay, please visit the Anti-CCP page.
A pioneering organisation focused on the development and manufacturing of important and innovative in vitro diagnostic tests for use in clinical laboratories.
As a general marker of overall health status, few tests carry greater predictive weight than Homocysteine. The amount of Homocysteine in your blood is one of the best independent indicators of how healthy you are.